# Fatty Liver and Type 2 Diabetes: A Study of Annual Healthcare Costs | Buy This GLP

A study of 17,412 matched pairs with type 2 diabetes found an adjusted $11,411 annual spending gap associated with a recorded fatty liver diagnosis.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/fatty-liver-annual-cost
Updated: 2026-11-15
Published: 2026-09-16

[← Research](https://buythisglp.com/research)

Evidence

# Fatty Liver and Type 2 Diabetes: A Study of Annual Healthcare Costs

Among matched adults with type 2 diabetes, health care spending was 62% higher after adjustment for those with a recorded fatty liver diagnosis.

Editorial profile: [Carla Medina](https://buythisglp.com/authors/carla-medina)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20264 min readUpdated November 2026

Mean total healthcare costs, one year · recorded MASLD · $29,734 · no recorded MASLD · $18,320 · Adjusted difference: $11,411 per person · 17,412 matched pairs with type 2 diabetes, ages 18–64

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   A U.S. claims study matched 17,412 pairs of adults aged 18–64 with type 2 diabetes, with and without a recorded fatty liver diagnosis.
-   Mean 12-month healthcare costs were $29,734 with diagnosed MASLD and $18,320 without a recorded diagnosis. The adjusted difference was $11,411.
-   The study counted payments from health plans and patients for care from all causes. It could not estimate what treating or preventing MASLD would save.

## What the study measured

Researchers started with 155,172 adults with type 2 diabetes in U.S. IQVIA health-plan claims from January 2016 through June 2025. They matched 17,412 adults with a recorded diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) to 17,412 adults without a recorded diagnosis and compared all-cause direct health care costs over 12 months [\[1\]](https://buythisglp.com/research/fatty-liver-annual-cost#ref-1).

The adjusted cost ratio was 1.62 (95% confidence interval 1.58–1.67). The statistical model estimated $11,411 more per person over 12 months (95% CI $10,725–$12,097). Hospital stays accounted for the largest estimated difference, $4,473 per person. The totals include what health plans and patients paid for hospital care, outpatient care, emergency visits and outpatient prescriptions, expressed in 2025 U.S. dollars [\[1\]](https://buythisglp.com/research/fatty-liver-annual-cost#ref-1).

What the medication subgroups compare

Among people receiving a GLP-1 receptor agonist, a recorded MASLD diagnosis was associated with $10,653 more in annual costs. Among people receiving an SGLT2 inhibitor, the estimated difference was $13,842. Each comparison held the medication group fixed and compared people with and without a recorded MASLD diagnosis. The results cannot show whether one drug lowers costs or whether either drug saves money compared with no treatment [\[1\]](https://buythisglp.com/research/fatty-liver-annual-cost#ref-1).

## How to interpret the spending difference

A comparison group without a recorded diagnosis may include people with undiagnosed MASLD. Guidance on [fatty liver screening in type 2 diabetes](https://buythisglp.com/research/should-you-be-screened-for-fatty-liver-with-diabetes) addresses how clinicians assess the risk of fibrosis. The study records could not distinguish spending by fibrosis stage. Differences in underlying health and health care use can remain after matching, so the study cannot establish how much of the spending gap the disease caused [\[1\]](https://buythisglp.com/research/fatty-liver-annual-cost#ref-1).

Estimates of [semaglutide’s cost-effectiveness for MASH](https://buythisglp.com/research/is-semaglutide-cost-effective-for-mash) address a separate question by modeling treatment costs and projected health benefits. The FDA’s accelerated approval for Wegovy injection covers adults with noncirrhotic MASH and moderate-to-advanced fibrosis, consistent with stages F2 to F3 [\[2\]](https://buythisglp.com/research/fatty-liver-annual-cost#ref-2). The claims study included a broader diagnosed MASLD population.

For a prescription, [GLP-1 coverage rules](https://buythisglp.com/research/does-insurance-cover-glp1) depend on the plan, the product and the condition being treated. The study’s combined spending figure cannot tell you what your insurer would cover or how much you would pay at the pharmacy.

## Frequently asked

How much higher were healthcare costs for people with fatty liver disease?

Among matched adults aged 18 to 64 with type 2 diabetes, the adjusted annual difference associated with a recorded MASLD diagnosis was $11,411 in 2025 U.S. dollars.

Does taking a GLP-1 lower that cost?

The study cannot answer that. Its GLP-1 subgroup compared people with and without a recorded MASLD diagnosis among those already receiving a GLP-1 drug.

Does the $11,411 estimate describe what a patient pays?

It combines payments from health plans and patients for hospital care, outpatient and emergency services, and prescriptions. It cannot estimate an individual’s out-of-pocket costs.

## Sources

1.  \[1\] Tran TH, et al. (2026). Real-World Cost and Utilisation Burden of Diagnosed Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes in the United States: A Retrospective Cohort Study Diabetes, Obesity and Metabolism. [PMID 42736030](https://pmc.ncbi.nlm.nih.gov/articles/PMC13731005/)
2.  \[2\] U.S. Food and Drug Administration (2025). Wegovy accelerated approval for noncirrhotic MASH with moderate-to-advanced liver fibrosis FDA. [Source](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215256Orig1s024ltr.pdf)

## Where to get it

### The cheapest GLP-1

Every seller that publishes a price, ordered lowest first on the standing month-to-month rate, plus the question to ask before you pay any of them.

[See the board →](https://buythisglp.com/best/cheapest-glp1)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
